Growth power meets the "core" trend. The 17th China Growth-Oriented Pharmaceutical Enterprise Development Conference, the 5th World Traditional Medicine Conference and World Traditional Chinese Medicine Service Trade Conference, hosted by the China Medical Materials Association, was held at the Xiamen Baixiang Convention and Exhibition Center on November 22nd.

Focusing on the new development concept, the conference held高峰论坛 and parallel sessions covering various aspects of pharmaceutical manufacturing, pharmaceutical commerce, medical services and other links, providing a platform to promote enterprise exchanges and cooperation, gain insight into industry trends, share innovative models, discuss development strategies, and promote resource sharing and collaborative innovation. Benefit participated in several professional forums to discuss the path of brand growth and innovation empowerment, and explore the high-quality development of the big health industry.

2023 World Ganoderma Conference

On November 24th, the first World Ganoderma Conference, hosted by the China Medical Materials Association and co-organized by the World Federation of Traditional Chinese Medicine Service Trade and Zhejiang Weikang Pharmaceutical Co., Ltd., was held during the 17th Growth Conference. The purpose of this Ganoderma Conference is to promote the authentic medicinal material Ganoderma, carry forward the world Ganoderma culture, and strengthen international exchanges and cooperation in Ganoderma industry, academia and research. A gathering of experts on site jointly discussed the prospects and future of the Ganoderma industry, explored the value and potential of Ganoderma, and worked together to build the industrial development blueprint of Chinese Ganoderma.

Zhang Liyun, Executive President of Benefit Pharmaceutical, was invited to deliver a keynote speech on "Billion-Yuan Single Product · The King of Medicines - Tetrastigma hemsleyanum", introducing another authentic medicinal material in Zhejiang - "the King of Medicines" Tetrastigma hemsleyanum. Starting from the promising market prospect of the traditional Chinese medicine big health industry, she mentioned that Tetrastigma hemsleyanum has a large-scale market potential in key fields such as clearing heat and detoxifying, preventing and fighting cancer, protecting the liver and dissipating knots, and insight into the development trend of Tetrastigma hemsleyanum. At the same time, she detailed the advantages of Zhejiang-produced Tetrastigma hemsleyanum. Although Tetrastigma hemsleyanum is a single traditional Chinese medicine, it is a natural plant antibiotic and a natural compound medicine, rich in a variety of natural medicinal ingredients, which gather to form unique medicinal effects. As a single traditional Chinese medicine, it can achieve a variety of therapeutic effects with remarkable efficacy, and the medicinal effects of Tetrastigma hemsleyanum are proved by papers and literatures. Finally, she introduced the advantages of Benefit's "Chu Sanqing" Tetrastigma hemsleyanum Powder, which is broad-spectrum, efficient, non-toxic, non-resistant and bidirectionally regulated, making it the best choice for常备 medicines in family medicine cabinets in the future.

The 2nd Forum on Innovation and Development of Traditional Chinese Medicine Marketing

On the morning of November 24th, the 2nd Forum on Innovation and Development of Traditional Chinese Medicine Marketing was successfully held. Chen Feng, Director of the Marketing Division of Benefit Pharmaceutical, was invited to participate in this forum and delivered a keynote speech on "Opportunities and Future of the Industrial Development of the King of Medicines - Tetrastigma hemsleyanum", introducing and sharing Tetrastigma hemsleyanum and its future development opportunities.

Subsequently, a roundtable forum was held, with special guests (in no particular order) including Wu Lihua, Chairman of Benefit Pharmaceutical; Chen Guoliang, Chairman of Shaanxi Guangjitang Pharmaceutical Group; Wang Hongfeng, Chairman of Guizhou Liansheng Pharmaceutical Group; Li Wenjie, Chairman of Shandong Shuyu Civilian Pharmacy Chain; Ji Zhenqiang, Deputy General Manager of Marketing of Yiling Pharmaceutical Group; and Wei Jihong, Chairman of Henan Chengyi Pharmaceutical, conducting a joint dialogue on the theme of "Innovation and Development of Traditional Chinese Medicine Marketing". Wu Lihua, Chairman of Benefit Pharmaceutical, shared his views on "Opportunities and Innovation in the Development of Traditional Chinese Medicine Formula Granules and the Whole Industry Chain" on site.

Chairman Wu Lihua stated that reaffirming the status of the national standards for traditional Chinese medicine formula granules is not only conducive to providing consumers with safer, more convenient and more effective traditional Chinese medicine products, but also provides a broader market space for the development of traditional Chinese medicine, promotes the standardization, normalization and modernization of the cause of traditional Chinese medicine, and drives the standardized and standardized development of the traditional Chinese medicine industry. How traditional Chinese medicine enterprises can make independent innovations in the research and development of traditional Chinese medicine formula granules and empower innovation in marketing, so as to better explore the path of high-quality development of the traditional Chinese medicine industry, is a question worthy of deep consideration.

With the important platform provided by this Growth Conference, Benefit Pharmaceutical has brought "Tetrastigma hemsleyanum", one of the new "Eight Flavors of Zhejiang", to more people's attention, enabling it to be carried forward and bringing health and hope to more patients with cancer, nodules and inflammation by reducing their suffering from diseases. As a practitioner of modern traditional Chinese medicine, Benefit, with a mission, fully promoted Zhejiang authentic medicinal materials and the brand characteristics of "Famous Medicines Produced in Zhejiang" to government leaders, experts, scholars and business elites at home and abroad who care about the traditional Chinese medicine industry and the development of the traditional Chinese medicine big health industry. Moreover, it made Benefit's "Chu Sanqing · Tetrastigma hemsleyanum Powder" shine in this forum, which not only conveyed the business card of Zhejiang but also fired the first shot in the marketing of Benefit's premium flagship product. In the future, Benefit will focus on the full-category development of Tetrastigma hemsleyanum, continuously expand the layout of the whole industry chain of Tetrastigma hemsleyanum, build the first national GAP planting base for Tetrastigma hemsleyanum, meticulously cultivate product quality, and set sail in the new era of health.